Raju Mohan Purchases 261,752 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan acquired 261,752 shares of the company’s stock in a transaction on Monday, November 25th. The shares were acquired at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the acquisition, the chief executive officer now directly owns 2,175,028 shares in the company, valued at $4,371,806.28. The trade was a 13.68 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Raju Mohan also recently made the following trade(s):

• On Friday, November 22nd, Raju Mohan purchased 238,248 shares of Ventyx Biosciences stock. The shares were bought at an average cost of $1.83 per share, with a total value of $435,993.84.

Ventyx Biosciences Trading Up 11.4 %

VTYX traded up $0.21 on Monday, hitting $2.06. 2,159,733 shares of the company’s stock were exchanged, compared to its average volume of 2,033,156. The stock has a fifty day moving average of $2.19 and a two-hundred day moving average of $2.64. Ventyx Biosciences, Inc. has a twelve month low of $1.67 and a twelve month high of $11.48. The firm has a market cap of $145.66 million, a PE ratio of -0.86 and a beta of 0.37.

Institutional Trading of Ventyx Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Palumbo Wealth Management LLC acquired a new position in Ventyx Biosciences during the 3rd quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. lifted its stake in Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Ventyx Biosciences during the second quarter valued at $32,000. Intech Investment Management LLC acquired a new position in shares of Ventyx Biosciences during the third quarter valued at $42,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after acquiring an additional 7,096 shares during the last quarter. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VTYX. Wells Fargo & Company reduced their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. Canaccord Genuity Group cut their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.